Genentech Inc

[TERIA]

New interview released with Daejin Abidoye, Medical Director from Roche-Genentech in the run up to his keynote address at Cancer Vaccines 2016 next month.

"As a Medical Director in Clinical Development, I help oversee the Genitourinary (GU) Malignancies program for our Immuno-Oncology Franchise. Our lead molecule, Atezolizumab, is a humanized engineered monoclonal antibody that selectively targets PD-L1 and has shown clinical activity in various solid tumor malignancies. As the Clinical Lead for Atezolizumab in Urothelial Cancer, I have led the clinical team through the growth of a comprehensive product development program in urothelial cancer, to the recent approval of atezolizumab for metastatic urothelial cancer (mUC) in the United States."

The full interview is available at http://www.smi-online.co.uk/goto/2016cancervaccinesevent.asp#tab_downloads